1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
May 2026 in “Acta Dermato Venereologica” Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
May 2026 in “Journal of Clinical Medicine” COVID-19 pandemic increased alopecia areata cases and hospitalizations.
April 2026 in “Meditsinskiy sovet = Medical Council” Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
February 2026 in “Journal of Advances in Biology & Biotechnology” Alopecia areata causes unpredictable hair loss and requires personalized treatment.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
January 2026 in “International Journal of Dermatology” The new tool helps measure the impact of alopecia areata on children's quality of life.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Vitamin A levels don't significantly affect alopecia areata.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Vitamin A levels don't significantly affect alopecia areata.
January 2026 in “Dermatologic Therapy” Higher RBP4 levels are linked to severe alopecia areata, but genetic variant rs3758539 doesn't affect baricitinib response.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
October 2025 in “Dermatology and Therapy” Adults with alopecia areata have a higher risk of mental health issues, especially women after COVID-19.
October 2025 in “Journal of Skin and Sexually Transmitted Diseases” Alopecia areata patients often have undetected thyroid issues, so routine thyroid screening is recommended.
September 2025 in “Journal of Clinical Medicine” Elevated granulysin levels may indicate disease activity in vitiligo and alopecia areata.
September 2025 in “Journal of the American Academy of Dermatology” Eyebrow and eyelash hair loss in alopecia areata worsens quality of life.
August 2025 in “Clinical and Experimental Dermatology” Alopecia areata treatments often don't lead to lasting improvement.
July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
May 2025 in “International Journal of Dermatology” Alopecia areata patients are more likely to develop systemic lupus erythematosus.
People with alopecia areata have more inflammation but similar heart risk as healthy people.
April 2025 in “Egyptian journal of Immunology” Calprotectin levels are higher in alopecia areata patients, indicating systemic inflammation.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” UVFD helps detect hair follicles in alopecia areata better than traditional methods.
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.
January 2025 in “Indian Journal of Paediatric Dermatology” Vitamin D deficiency is common in children with and without alopecia areata, and more research is needed.
December 2024 in “Reports of Vinnytsia National Medical University” Men with alopecia areata have different body proportions, with shorter legs and longer upper bodies.
December 2024 in “IntechOpen eBooks” Trichoscopy helps diagnose and track alopecia areata by examining specific hair and scalp markers.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Patients with anxiety or depression report more severe alopecia areata.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Disease-specific tools better assess quality of life in alopecia areata patients.
Mesenchymal Stem Cell Conditioned Media can significantly regrow hair in alopecia areata patients.
October 2024 in “Asian Journal of Pharmaceutical and Clinical Research” Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.